00018091222025-01-012025-06-300001809122cvac:BiontechSEMembercvac:CurevacNVMemberifrs-full:TopOfRangeMembersrt:ScenarioForecastMember2025-06-122025-06-120001809122cvac:BiontechSEMembercvac:CurevacNVMemberifrs-full:BottomOfRangeMembersrt:ScenarioForecastMember2025-06-122025-06-120001809122cvac:CrisprMember2025-04-012025-06-300001809122cvac:CrisprMember2025-01-012025-06-300001809122cvac:GlaxosmithklineMember2024-04-012024-06-300001809122cvac:CrisprMember2024-04-012024-06-300001809122cvac:GlaxosmithklineMember2024-01-012024-06-300001809122cvac:CrisprMember2024-01-012024-06-300001809122cvac:ResearchAndDevelopmentServicesMemberifrs-full:GoodsOrServicesTransferredOverTimeMember2025-04-012025-06-300001809122cvac:ResearchAndDevelopmentServicesCombinedWithIpLicenseMemberifrs-full:GoodsOrServicesTransferredOverTimeMember2025-04-012025-06-300001809122country:CHcvac:CrisprMember2025-04-012025-06-300001809122country:BEcvac:GlaxosmithklineMember2025-04-012025-06-300001809122ifrs-full:GoodsOrServicesTransferredOverTimeMember2025-04-012025-06-300001809122cvac:ResearchAndDevelopmentServicesMemberifrs-full:GoodsOrServicesTransferredOverTimeMember2025-01-012025-06-300001809122cvac:ResearchAndDevelopmentServicesCombinedWithIpLicenseMemberifrs-full:GoodsOrServicesTransferredOverTimeMember2025-01-012025-06-300001809122cvac:IfrsProductMemberifrs-full:GoodsOrServicesTransferredAtPointInTimeMember2025-01-012025-06-300001809122country:CHcvac:CrisprMember2025-01-012025-06-300001809122country:BEcvac:GlaxosmithklineMember2025-01-012025-06-300001809122ifrs-full:GoodsOrServicesTransferredOverTimeMember2025-01-012025-06-300001809122ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember2025-01-012025-06-300001809122cvac:ResearchAndDevelopmentServicesMemberifrs-full:GoodsOrServicesTransferredOverTimeMember2024-04-012024-06-300001809122cvac:ResearchAndDevelopmentServicesCombinedWithIpLicenseMemberifrs-full:GoodsOrServicesTransferredOverTimeMember2024-04-012024-06-300001809122cvac:IfrsProductMemberifrs-full:GoodsOrServicesTransferredAtPointInTimeMember2024-04-012024-06-300001809122cvac:GlaxosmithklineMembercvac:ResearchAndDevelopmentServicesMember2024-04-012024-06-300001809122country:CHcvac:CrisprMember2024-04-012024-06-300001809122country:BEcvac:GlaxosmithklineMember2024-04-012024-06-300001809122ifrs-full:GoodsOrServicesTransferredOverTimeMember2024-04-012024-06-300001809122ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember2024-04-012024-06-300001809122cvac:ResearchAndDevelopmentServicesMemberifrs-full:GoodsOrServicesTransferredOverTimeMember2024-01-012024-06-300001809122cvac:ResearchAndDevelopmentServicesCombinedWithIpLicenseMemberifrs-full:GoodsOrServicesTransferredOverTimeMember2024-01-012024-06-300001809122cvac:IfrsProductMemberifrs-full:GoodsOrServicesTransferredAtPointInTimeMember2024-01-012024-06-300001809122cvac:GlaxosmithklineMembercvac:ResearchAndDevelopmentServicesMember2024-01-012024-06-300001809122cvac:CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMembercvac:GlaxosmithklineMember2024-01-012024-06-300001809122country:CHcvac:CrisprMember2024-01-012024-06-300001809122country:BEcvac:GlaxosmithklineMember2024-01-012024-06-300001809122ifrs-full:GoodsOrServicesTransferredOverTimeMember2024-01-012024-06-300001809122ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember2024-01-012024-06-300001809122cvac:BiontechSEMembercvac:CurevacNVMembersrt:ScenarioForecastMember2025-06-122025-06-120001809122ifrs-full:PreferenceSharesMember2025-06-300001809122ifrs-full:OrdinarySharesMember2025-06-300001809122ifrs-full:ShareOptionsMembercvac:SupervisoryBoardMembersMember2025-02-242025-02-240001809122ifrs-full:ShareOptionsMembercvac:MembersOfExecutiveBoardAndVariousKeyEmployeesMember2025-02-242025-02-240001809122ifrs-full:ShareOptionsMembercvac:KeyEmployeesMember2025-01-012025-01-010001809122cvac:SellingAndDistributionExpensesMember2025-04-012025-06-300001809122cvac:OtherOperatingExpensesMember2025-04-012025-06-300001809122cvac:SellingAndDistributionExpensesMember2025-01-012025-06-300001809122cvac:OtherOperatingExpensesMember2025-01-012025-06-300001809122cvac:SellingAndDistributionExpensesMember2024-04-012024-06-300001809122cvac:OtherOperatingExpensesMember2024-04-012024-06-300001809122cvac:SellingAndDistributionExpensesMember2024-01-012024-06-300001809122cvac:OtherOperatingExpensesMember2024-01-012024-06-300001809122ifrs-full:RetainedEarningsMember2025-06-300001809122ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2025-06-300001809122ifrs-full:IssuedCapitalMember2025-06-300001809122ifrs-full:CapitalReserveMember2025-06-300001809122ifrs-full:RetainedEarningsMember2024-12-310001809122ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2024-12-310001809122ifrs-full:IssuedCapitalMember2024-12-310001809122ifrs-full:CapitalReserveMember2024-12-310001809122ifrs-full:RetainedEarningsMember2024-06-300001809122ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2024-06-300001809122ifrs-full:IssuedCapitalMember2024-06-300001809122ifrs-full:CapitalReserveMember2024-06-300001809122ifrs-full:RetainedEarningsMember2023-12-310001809122ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2023-12-310001809122ifrs-full:IssuedCapitalMember2023-12-310001809122ifrs-full:CapitalReserveMember2023-12-310001809122cvac:MembersOfExecutiveBoardAndVariousKeyEmployeesMember2025-01-012025-06-300001809122cvac:KeyEmployeesMember2025-01-012025-06-300001809122ifrs-full:RetainedEarningsMember2025-01-012025-06-300001809122ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2025-01-012025-06-300001809122ifrs-full:RetainedEarningsMember2024-01-012024-06-300001809122ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2024-01-012024-06-300001809122cvac:CurevacNVMember2025-08-310001809122cvac:LongTermIncentivePlanMembercvac:MembersOfExecutiveBoardAndVariousKeyEmployeesMember2025-02-242025-02-240001809122cvac:LongTermIncentivePlanMembercvac:KeyEmployeesMember2025-01-012025-01-010001809122cvac:GlaxosmithklineMember2025-06-300001809122cvac:CrisprMember2025-06-3000018091222020-11-302020-11-3000018091222025-01-012025-03-3100018091222024-01-012024-03-310001809122ifrs-full:IssuedCapitalMember2025-01-012025-06-300001809122ifrs-full:IssuedCapitalMember2024-01-012024-06-300001809122cvac:GlaxosmithklineMember2025-08-310001809122ifrs-full:CapitalReserveMember2025-01-012025-06-300001809122ifrs-full:CapitalReserveMember2024-01-012024-06-300001809122ifrs-full:CostOfSalesMember2025-04-012025-06-300001809122ifrs-full:CostOfSalesMember2025-01-012025-06-300001809122cvac:LargestShareholderMember2025-06-300001809122cvac:GlaxosmithklineMember2025-08-012025-08-310001809122cvac:CurevacNVMember2025-08-012025-08-310001809122ifrs-full:LegalProceedingsProvisionMember2024-07-012024-07-310001809122ifrs-full:LegalProceedingsProvisionMember2024-05-012024-05-310001809122cvac:BiontechSEMember2025-06-1200018091222025-06-1200018091222020-11-300001809122cvac:BiontechSEMembercvac:CurevacNVMembersrt:ScenarioForecastMember2025-06-120001809122cvac:IfrsResearchAndDevelopmentExpenseMember2025-04-012025-06-300001809122cvac:IfrsGeneralAndAdministrativeExpenseMember2025-04-012025-06-300001809122cvac:IfrsResearchAndDevelopmentExpenseMember2025-01-012025-06-300001809122cvac:IfrsGeneralAndAdministrativeExpenseMember2025-01-012025-06-300001809122ifrs-full:CostOfSalesMember2024-04-012024-06-300001809122cvac:IfrsResearchAndDevelopmentExpenseMember2024-04-012024-06-300001809122cvac:IfrsGeneralAndAdministrativeExpenseMember2024-04-012024-06-300001809122ifrs-full:CostOfSalesMember2024-01-012024-06-300001809122cvac:IfrsResearchAndDevelopmentExpenseMember2024-01-012024-06-300001809122cvac:IfrsGeneralAndAdministrativeExpenseMember2024-01-012024-06-3000018091222024-01-012024-12-310001809122cvac:BiontechSEMembercvac:CurevacNVMemberdei:AdrMembersrt:ScenarioForecastMember2025-06-120001809122ifrs-full:ShareOptionsMember2025-04-012025-06-300001809122cvac:RsuSupervisoryBoardMember2025-04-012025-06-300001809122cvac:LongTermIncentivePlanAndRestrictedStockUnitMember2025-04-012025-06-3000018091222025-04-012025-06-300001809122ifrs-full:ShareOptionsMember2025-01-012025-06-300001809122cvac:RsuSupervisoryBoardMember2025-01-012025-06-300001809122cvac:LongTermIncentivePlanAndRestrictedStockUnitMember2025-01-012025-06-300001809122ifrs-full:ShareOptionsMember2024-04-012024-06-300001809122cvac:RsuSupervisoryBoardMember2024-04-012024-06-300001809122cvac:PriorVirtualStockOptionsPlanMember2024-04-012024-06-300001809122cvac:LongTermIncentivePlanAndRestrictedStockUnitMember2024-04-012024-06-3000018091222024-04-012024-06-300001809122ifrs-full:ShareOptionsMember2024-01-012024-06-300001809122cvac:RsuSupervisoryBoardMember2024-01-012024-06-300001809122cvac:PriorVirtualStockOptionsPlanMember2024-01-012024-06-300001809122cvac:LongTermIncentivePlanAndRestrictedStockUnitMember2024-01-012024-06-3000018091222025-06-3000018091222025-03-3100018091222024-12-3100018091222024-06-3000018091222024-03-3100018091222023-12-310001809122cvac:CurevacNVMember2025-06-120001809122ifrs-full:LegalProceedingsProvisionMember2024-01-012024-06-3000018091222024-01-012024-06-30iso4217:EURiso4217:USDxbrli:sharesiso4217:USDxbrli:sharesxbrli:purecvac:itemiso4217:EURxbrli:sharescvac:Ycvac:OptionUNITED STATES SECURITIES AND EXCHANGE COMMISSION

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

~~REPORT~~For OFthe ~~FOREIGN~~month ~~PRIVATE~~of ~~ISSUER~~October 2025

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number: 001-39446

CureVac N.V.

(Exact Name of Registrant as Specified in Its Charter)

Friedrich-Miescher-Strasse 15, 72076

Tübingen, Germany

+49 7071 9883 0

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

~~Indicate by check mark whether the registrant files or will file annual reports under cover of~~ Form 20-F or x Form 40-F: ¨

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes ¨ No x

Yes ☐ No ☒

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes ¨ No x

~~Yes~~On ☐October 24, No2025, ☒CureVac N.V. (the “Company”) convened an extraordinary general meeting of shareholders to be held on November 25, 2025 and made available to its shareholders certain other materials in connection with such meeting.

The information included in this Form 6-K (including Exhibit 99.1, Exhibit 99.2, Exhibit 99.3 and Exhibit 99.4) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

This Report of Foreign Private Issuer on Form 6-K (this “Form 6-K”) is being furnished by CureVac N.V. (“CureVac”) to the Securities and Exchange Commission (the “SEC”) for the sole purposes of: (i) furnishing, as Exhibit 99.1 to this Form 6-K, Unaudited Interim Condensed Consolidated Financial Statements announcing CureVac’s financial results and business updates as of June 30, and for the three and six months ended June 30, 2025 and 2024; and (ii) furnishing, as Exhibit 99.2 to this Form 6-K, Management’s Discussion and Analysis of Financial Condition and Results of Operations, which discusses and analyzes CureVac’s financial condition and results of operations as of June 30, 2025 and for the six month periods ended June 30, 2025 and 2024.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CureVac N.V.
	(Registrant)

Date: October 24, 2025	By:	/s/ Alexander Zehnder
		Chief Executive Officer


CUREVAC N.V.

By:	/s/Axel Sven Malkomes	By:	/s/Alexander Zehnder
	Chief Financial Officer		Chief Executive Officer


Date: August 15, 2025

EXHIBIT INDEX

EXHIBIT NO.		DESCRIPTION
99.1		Convening notice to the extraordinary general meeting of shareholders including agenda and explanatory notes.
99.2		Voting proxy.
99.3		Merger proposal
99.4		Explanatory notes to the merger proposal

EXHIBIT NO.		DESCRIPTION
99.1		Unaudited Interim Condensed Consolidated Financial Statements as of June 30, 2025 and for the three and six months ended June 30, 2025 and 2024
99.2		Management’s Discussion and Analysis of Financial Condition and Results of Operations

Filing Compare · CureVac N.V.